Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. Despite advances in understanding its genetic basis, particularly mutations in Chromosome 9 Open Reading Frame 72 (C9orf72), superoxide dismutase 1 (SOD1), TAR DNA-binding protein (TARDBP), and Fused in Sarcoma (FUS) gene, current diagnostic methods result in delayed intervention, and available treatments offer only modest benefits. This review examines innovative approaches transforming ALS research and clinical management. We explore emerging biomarkers, including the fluid-based markers such as neurofilament light chain, exosomes, and microRNAs in biological fluids, alongside the non-fluid-based biomarkers, including neuroimaging and electrophysiological markers, for early diagnosis and patient stratification. The integration of multi-omics data reveals complex molecular mechanisms underlying ALS heterogeneity, potentially identifying novel therapeutic targets. We highlight current gene therapy strategies, including antisense oligonucleotides (ASOs), RNA interference (RNAi), and CRISPR/Cas9 gene editing systems, alongside advanced delivery methods for crossing the blood–brain barrier. By bridging molecular neuroscience with bioengineering, these technologies promise to revolutionize ALS diagnosis and treatment, advancing toward truly disease-modifying interventions for this previously intractable condition.
Efficient intracellular delivery remains a major bottleneck in nucleic acid–based therapeutics. Among non-viral vectors, poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) offers tunable cationic properties and synthetic versatility, yet its limited endosomal escape capacity constrains transfection efficiency (TE). In this work, PDMAEMA-based polyplexes were systematically investigated to elucidate how molecular weight (MW), macromolecular architecture (linear vs. star-shaped), and hydrophobic modification with poly(ε-polycaprolactone) (PCL) influence gene delivery performance. To this end, a library of cationic polymers was synthesized via Atom Transfer Radical Polymerization (ATRP) and characterized in terms of DNA condensation ability, polyplex physicochemical properties, cytotoxicity (CT), and TE. Linear PDMAEMA (L-PDMAEMA) in the medium- and high-MW ranges (10-20 kDa) provided the optimal balance between charge density and colloidal stability, achieving TE comparable to the benchmark 25 kDa branched polyethyleneimine (bPEI) while exhibiting significantly lower CT. Conversely, star-shaped and micellar architectures exhibited reduced TE, likely due to steric hindrance affecting charge accessibility. To overcome endosomal entrapment, chloroquine (CQ) was employed as an endosomal escape enhancer, resulting in up to a 30-fold increase in TE for L-PDMAEMA without measurably affecting cell viability. Overall, this study demonstrates that rational tuning of polymer topology and MW enables PDMAEMA-based vectors to combine high TE with minimal CT, emphasizing the potential of integrating intrinsic endosomal escape functionality in future polymer designs.
16 June 2026 in Journal of Drug Delivery Science and Technology